Definition and epidemiology
Hyperlipidemia refers to abnormally elevated levels of lipids in the blood, including total cholesterol, LDL cholesterol (LDL-C), triglycerides, or a combination. It is classified broadly into:
- Primary (familial) hyperlipidemia - caused by inherited mutations affecting lipid metabolism
- Secondary hyperlipidemia - caused by diet, obesity, diabetes, hypothyroidism, nephrotic syndrome, cholestasis, or medications (thiazides, corticosteroids, estrogens, protease inhibitors)
It is extremely common worldwide, affecting a large proportion of adults in industrialized countries, and prevalence rises with age, obesity, and dietary patterns high in saturated fat and refined carbohydrates. Familial hypercholesterolemia (FH), the most common severe monogenic form, affects roughly 1 in 200-250 people in most populations, though many remain undiagnosed.
- LDL-C is the primary therapeutic target for cardiovascular risk reduction, not total cholesterol
- Tendon xanthomas (especially Achilles) are classic for familial hypercholesterolemia
- Triglycerides above roughly 1000 mg/dL raise acute pancreatitis risk, not atherosclerosis risk directly
- Statins remain first-line therapy across all major guidelines regardless of regional differences
- Secondary causes (hypothyroidism, diabetes, nephrotic syndrome) must be excluded before labeling as primary
- Corneal arcus and xanthelasma can occur even without lipid abnormality, especially in older patients
- FH follows autosomal dominant inheritance via LDL receptor mutation in most cases
- Treatment decisions are based on overall ASCVD risk score, not LDL-C level alone
Etiology and risk factors
Primary causes
- Familial hypercholesterolemia (FH) - autosomal dominant, LDL receptor mutation (most common), also apoB or PCSK9 mutations
- Familial combined hyperlipidemia - elevated LDL and triglycerides, strong premature CAD family history
- Familial hypertriglyceridemia - elevated VLDL/triglycerides
- Lipoprotein lipase or apoC-II deficiency - severe hypertriglyceridemia, risk of pancreatitis
Secondary causes
- Diabetes mellitus and metabolic syndrome
- Hypothyroidism
- Nephrotic syndrome
- Cholestatic liver disease
- Obesity, sedentary lifestyle, excess alcohol
- Drugs: thiazide diuretics, beta-blockers, corticosteroids, oral estrogens, antiretroviral protease inhibitors, atypical antipsychotics
Risk factors
- Family history of premature cardiovascular disease
- Obesity, poor diet (saturated/trans fat, refined sugar)
- Smoking, physical inactivity
- Age, male sex (premenopausal women are relatively protected)
Pathophysiology
Cholesterol and triglycerides are transported in the blood as lipoproteins (chylomicrons, VLDL, LDL, HDL). Elevated LDL-C promotes atherosclerosis: LDL particles infiltrate the arterial intima, undergo oxidation, and are engulfed by macrophages to form foam cells, triggering a chronic inflammatory response that builds fibrous atherosclerotic plaques. These plaques narrow arteries and can rupture, causing acute thrombotic events (myocardial infarction, stroke).
High triglycerides, particularly from chylomicrons and VLDL, are less directly atherogenic but at very high levels (typically above roughly 1000 mg/dL) cause acute pancreatitis through capillary obstruction by triglyceride-rich lipoproteins and local fatty acid-induced injury.
HDL cholesterol is traditionally considered protective via reverse cholesterol transport, though raising HDL pharmacologically has not reliably reduced cardiovascular events, which is why LDL-C remains the primary treatment target.
Clinical features
Most patients are asymptomatic, and hyperlipidemia is detected on routine screening lipid panels. Severe or longstanding cases may show physical signs:
- Xanthelasma - yellowish plaques on the eyelids
- Tendon xanthomas - especially Achilles tendon, classic for FH
- Corneal arcus (arcus senilis) - lipid deposition at corneal margin
- Eruptive xanthomas - small yellow papules, seen with severe hypertriglyceridemia
- Lipemia retinalis - creamy appearance of retinal vessels with very high triglycerides
Severe hypertriglyceridemia (generally above 1000 mg/dL) can present with recurrent episodes of acute pancreatitis. End-organ consequences of chronic atherosclerosis (angina, claudication, stroke symptoms) may be the presenting complaint in undiagnosed or untreated patients.
Diagnosis
Diagnosis relies on a fasting or non-fasting lipid panel measuring total cholesterol, LDL-C, HDL-C, and triglycerides (fasting preferred when triglycerides are markedly elevated).
Screening
- Universal screening is recommended starting in young adulthood (around age 20) and repeated periodically
- Children with family history of FH or premature CAD should be screened earlier
Additional work-up
- Rule out secondary causes: TSH, fasting glucose/HbA1c, renal function, liver function, urinalysis for proteinuria
- Genetic or clinical criteria (e.g., Dutch Lipid Clinic Network criteria) support diagnosis of FH when LDL-C is markedly elevated with tendon xanthomas and/or strong family history
- Cardiovascular risk calculators (e.g., ASCVD pooled cohort equations, SCORE2 in Europe) integrate lipid values with other risk factors to guide treatment intensity
| Lipid parameter | Clinically notable threshold |
|---|---|
| LDL-C | Elevated above 100-130 mg/dL depending on risk category |
| Triglycerides | Elevated above 150 mg/dL; severe above 500-1000 mg/dL |
| HDL-C | Low below roughly 40 mg/dL (men), 50 mg/dL (women) |
Differential diagnosis
- Secondary dyslipidemia from hypothyroidism, diabetes, or nephrotic syndrome - look for underlying disease markers rather than treating lipids alone
- Familial hypercholesterolemia vs familial combined hyperlipidemia - FH has isolated very high LDL-C with tendon xanthomas; combined hyperlipidemia has mixed LDL and triglyceride elevation
- Sitosterolemia - rare genetic disorder with xanthomas and elevated plant sterols, mimics FH
- Drug-induced dyslipidemia - temporal relationship to new medication
- Dysbetalipoproteinemia (type III) - apoE2/E2 genotype, palmar xanthomas, mixed hyperlipidemia
Management
Management is guided by estimated atherosclerotic cardiovascular disease (ASCVD) risk, not lipid numbers alone, per major guidelines (ACC/AHA, ESC/EAS). Approaches are broadly similar internationally but differ in specific LDL-C targets and risk thresholds.
Lifestyle modification (first step for all patients)
- Dietary changes: reduce saturated and trans fat, increase fiber, fruits, vegetables
- Regular aerobic exercise
- Weight loss if overweight/obese
- Smoking cessation, limit alcohol
Pharmacologic therapy
- Statins (HMG-CoA reductase inhibitors) - first-line for LDL-C lowering in essentially all guidelines; reduce cardiovascular events and mortality
- Ezetimibe - added when statin alone is insufficient; inhibits intestinal cholesterol absorption
- PCSK9 inhibitors (evolocumab, alirocumab) - for very high-risk patients or FH not controlled on statin plus ezetimibe
- Bempedoic acid - alternative/add-on, especially for statin-intolerant patients
- Fibrates - primarily for severe hypertriglyceridemia to reduce pancreatitis risk
- Omega-3 fatty acids (icosapent ethyl) - for persistent hypertriglyceridemia in high-risk patients
- Bile acid sequestrants - second-line agents that are not systemically absorbed; sometimes considered in pregnancy for this reason, but they are not a routine first-choice 'pregnancy-safe' therapy, and lifestyle modification remains the primary approach for lipid management in pregnant patients
Special situations
- Secondary causes should be treated/corrected before or alongside lipid-lowering therapy
- FH often requires high-intensity statin plus ezetimibe and/or PCSK9 inhibitor, sometimes LDL apheresis in homozygous FH
- Statins are contraindicated in pregnancy; lifestyle modification is the primary management approach, with bile acid sequestrants used only cautiously in select cases due to risk of fat-soluble vitamin malabsorption
Complications and prognosis
- Atherosclerotic cardiovascular disease: coronary artery disease, myocardial infarction, ischemic stroke, peripheral artery disease
- Acute pancreatitis from severe hypertriglyceridemia
- Untreated FH carries markedly elevated lifetime risk of premature coronary disease, often presenting in the 30s-40s if homozygous
With appropriate statin-based therapy and risk factor control, cardiovascular risk is substantially reduced, though hyperlipidemia itself is a chronic condition requiring long-term management rather than a one-time cure.
Xanthoma sites in FH - 'TAC': Tendon (Achilles), Arcus (corneal), Cutaneous (xanthelasma). Separately remember that FH classically shows isolated, markedly elevated LDL-C without hypertriglyceridemia.
Practice questions
1. A 45-year-old man with no significant past medical history undergoes routine screening and is found to have an LDL-C of 165 mg/dL. Physical exam reveals nodular thickening of both Achilles tendons. His father died of a myocardial infarction at age 42. Which of the following is the most likely diagnosis?
2. A 38-year-old woman with poorly controlled type 2 diabetes presents with acute severe epigastric pain radiating to the back. Lipase is markedly elevated. Lipid panel shows triglycerides of 2200 mg/dL. Which mechanism best explains her presentation?
3. A 55-year-old man with hyperlipidemia is started on a high-intensity statin. Three months later, repeat lipid panel shows LDL-C remains above goal despite good adherence and lifestyle changes. Which medication is the most appropriate next addition according to current guidelines?
Frequently asked questions
What causes hyperlipidemia?
Hyperlipidemia results from either genetic lipid metabolism disorders (like familial hypercholesterolemia) or secondary factors such as poor diet, obesity, diabetes, hypothyroidism, kidney disease, or certain medications. Genetic forms involve defective clearance of LDL particles, while secondary causes increase lipid production or reduce clearance through metabolic or hormonal disruption. Most adult cases involve a combination of modest genetic predisposition and lifestyle factors.
What are the first symptoms of hyperlipidemia?
Hyperlipidemia usually causes no symptoms at all and is found incidentally on routine blood tests. In severe or longstanding cases, visible signs can appear, including yellowish eyelid plaques (xanthelasma), tendon xanthomas, or a grayish ring around the cornea. Very high triglycerides may cause abdominal pain from pancreatitis before cholesterol levels are even checked.
How is hyperlipidemia diagnosed?
Diagnosis is made with a fasting or non-fasting blood lipid panel measuring total cholesterol, LDL-C, HDL-C, and triglycerides. Additional tests check for secondary causes like thyroid dysfunction, diabetes, or kidney disease. Risk calculators then combine these lipid values with age, blood pressure, smoking status, and other factors to estimate cardiovascular risk and guide treatment intensity.
Is hyperlipidemia curable?
Hyperlipidemia is generally a chronic condition rather than something that is permanently cured, though secondary causes can sometimes be fully reversed by treating the underlying problem. Primary genetic forms like familial hypercholesterolemia require lifelong management with statins and often additional medications. Lifestyle changes can meaningfully lower lipid levels but rarely normalize them completely in genetic cases.
Hyperlipidemia vs atherosclerosis — what is the difference?
Hyperlipidemia is the laboratory finding of elevated blood lipids, while atherosclerosis is the structural disease process of plaque buildup in artery walls that elevated LDL cholesterol helps cause over years. Hyperlipidemia is a risk factor that can exist without any detectable arterial disease yet, whereas atherosclerosis is the downstream consequence that leads to heart attacks and strokes. Treating hyperlipidemia aims to prevent or slow atherosclerosis.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E78
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.